

David Viñal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7135829/publications.pdf>

Version: 2024-02-01

17
papers

150
citations

1163117
8
h-index

1199594
12
g-index

20
all docs

20
docs citations

20
times ranked

215
citing authors

#	ARTICLE	IF	CITATIONS
1	Yttrium-90 transarterial radioembolization in patients with gastrointestinal malignancies. <i>Clinical and Translational Oncology</i> , 2022, 24, 796-808.	2.4	4
2	Clinicopathological characteristics and outcomes of patients with deficient mismatch repair colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 181-181.	1.6	1
3	Inâ€depth proteomics characterization of ^{67}Cu effectors identifies key proteins with diagnostic potential implicated in lymphangiogenesis, vasculogenesis and metastasis in colorectal cancer. <i>Molecular Oncology</i> , 2022, 16, 2672-2692.	4.6	4
4	Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. <i>JCO Clinical Cancer Informatics</i> , 2022, , .	2.1	7
5	Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy. <i>Clinical and Translational Oncology</i> , 2021, 23, 1185-1192.	2.4	12
6	Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience. <i>Clinical and Translational Oncology</i> , 2021, 23, 1245-1252.	2.4	21
7	Genomic profiling in non-small-cell lung cancer in young patients. A systematic review. <i>ESMO Open</i> , 2021, 6, 100045.	4.5	18
8	Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience. <i>Clinical and Translational Oncology</i> , 2021, 23, 1838-1846.	2.4	1
9	^{67}Cu , TAp73 and $^{133}\text{p}53$ Extracellular Vesicle Cargo as Early Diagnosis Markers in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 2240.	3.7	3
10	Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review. <i>ESMO Open</i> , 2021, 6, 100223.	4.5	18
11	Gp-100 as a Novel Therapeutic Target in Uveal Melanoma. <i>Cancers</i> , 2021, 13, 5968.	3.7	16
12	Efficacy of capecitabine when used concomitantly with proton pump inhibitors in cancer patients: a systematic review. <i>Clinical and Translational Oncology</i> , 2020, 22, 1288-1294.	2.4	5
13	Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas. <i>Clinical and Translational Oncology</i> , 2020, 22, 1849-1856.	2.4	12
14	Genomic profiling in oncology clinical practice. <i>Clinical and Translational Oncology</i> , 2020, 22, 1430-1439.	2.4	4
15	Epidemiology and natural history of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa patients: 20 years' experience of a reference centre in Spain. <i>Clinical and Translational Oncology</i> , 2019, 21, 1573-1577.	2.4	11
16	Efficacy of rechallenge with BRAF inhibition therapy in patients with advanced BRAFV600 mutant melanoma. <i>Clinical and Translational Oncology</i> , 2019, 21, 1061-1066.	2.4	11
17	Radium 223 for the treatment of metastatic castration-resistant prostate cancer. <i>Archivos Espanoles De Urologia</i> , 2019, 72, 500-507.	0.2	1